Abstract
C1 inhibitor, although frequently considered primarily a complement protein, is able to inactivate proteinases that participate in several different proteolytic cascades, and is essential in the regulation of activation of both the complement system and the contact system of kinin formation. It also may serve a backup function in regulation of coagulation and of fibrinolysis. C1 inhibitor, therefore, is most important in host defense and in the mediation of vascular permeability. Its name is derived from its discovery as the inactivator of the first complement component. This came about as a result of the studies of Lepow and his colleagues in the late 1950s and early 1960s; these were directed toward the isolation of C1 and its constituent subunits: C1q, C1r and C1s1–5. C1 inhibitor was characterized as a heat labile serum protein that inhibited the esterolytic activity of C1 and its proteolytic activity against C4 and C2. It subsequently was shown to inactivate several other plasma proteases, including kallikrein, plasmin, tissue plasminogen activator, and coagulation factors XIa and XIIa (Hageman factor)5–10. The fact that C1 inhibitor inactivated proteases by formation of denaturant stable equimolar complexes was first clearly shown by Harpel and Cooper with both C1s and plasmin6. Cl inhibitor does not appear to differ in any significant way from other serpins in its mechanism of action. The P1 and P1’ residues are arginine and threonine, respectively11.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Pensky, J., L. R. Levy, and I. H. Lepow. 1961. Partial purification of a serum inhibitor of C’1 esterase. J Biol Chem. 236:1674–1679.
Lepow, I. H., O. D. Ratnoff, F. S. Rosen, and L. Pillemer. 1956. Observations on a proesterase associated with partially purified first component of complement (C1). Proc Soc Exp Biol Med. 92:32 –37.
Lepow, I. H., O. D. Ratnoff, and L. R. Levy. 1958. Studies on the activation of a proesterase associated with partially purified first component of human complement. J Exp Med. 107:451–474.
Levy, L. R., and I. H. Lepow. 1959. Assay and properties of serum inhibitor of C’ 1 esterase. Proc Soc Exp Biol Med. 101:608–611.
Ratnoff, O. D., and I. H. Lepow. 1957. Some properties of an esterase derived from preparations of the first component of complement. J Exp Med. 106:327–343.
Harpel, P. C., and N. R. Cooper. 1975. Studies on human plasma C1–inactivator–enzyme interactions. I. Mechanisms of interaction with C1s, plasmin and trypsin. J Clin Invest. 55:593–604.
Ratnoff, O. D., J. Pensky, D. Ogston, and G. B. Naff. 1969. The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C1’r subcomponent of complement by serum C1’ esterase inhibitor. J Exp Med. 129:315–331.
Gigli, I., J. W. Mason, R. W. Colman, and K. F. Austen. 1970. Interaction of plasma kallikrein with the C1 inhibitor. Jlmmunol. 104:574–581.
Forbes, C. D., J. Pensky, and O. D. Ratnoff. 1970. Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified C1 inactivator. J Lab Clin Med. 76:809–815.
Schreiber, A. D., A. P. Kaplan, and K. F. Austen. 1973. Inhibition by C1–INH of Hageman factor fragment activation of coagulation, fibrinolysis, and kinin generation. J Clin Invest. 52:1402–1409.
Salvesen, G. S., J. J. Catanese, L. F. Kress, and J. Travis. 1985. Primary structure of the reactive site of human C1–inhibitor. J Biol Chem. 260:2432–6.
Donaldson, V. H., and R. R. Evans. 1963. A biochemical abnormality in hereditary angioneurotic edema. Am J Med. 35:37–44.
Landerman, N. S., M. E. Webster, E. L. Becker, and H. H. Ratcliffe. 1962. Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein. J Allergy. 33:330–341.
Haupt, H., N. Heimburger, T. Kranz, and H. G. Schwick. 1970. Ein beitrag zur isolierung und characterisierung des C1–inaktivators aus humanplasma. Eur J Biochem. 17:254–261.
Bock, S. C., K. Skriver, E. Nielsen, H. C. Thogersen, B. Wiman, V. H. Donaldson, R. L. Eddy, J. Marrinan, E. Radziejewska, R. Huber, T. B. Shows, and S. Magnussen. 1986. Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization. Biochemistry. 25:4292–4301.
Reboul, A., G. J. Arlaud, R. B. Sim, and M. G. Colomb. 1977. A simplified procedure for the purification of C1–inactivator from human plasma. Interaction with complement subcomponents C1r and C1 s. FEBS Lett. 79:45–50.
Harrison, R. A. 1983. Human C1 inhibitor: improved isolation and preliminary structural characterization. Biochemistry. 22:5001–5007.
Nilsson, T., and B. Wiman. 1982. Purification and characterization of human C1–esterase inhibitor. Biochim Biophys Acta. 705:271–276.
Perkins, S. J., K. F. Smith, S. Amatayakul, D. Ashford, T. W. Rademacher, R. A. Dwek, P. J. Lachmann, and R. A. Harrison. 1990. Two–domain structure of the native and reactive centre cleaved forms of C1 inhibitor of human complement by neutron scattering. J Mol Biol. 214:751–763.
Odermatt, E., H. Berger, and Y. Sano. 1981. Size and shape of human C1–inhibitor. FEBS Lett. 131:283–285.
Eldering, E., E. Verpy, D. Roem, T. Meo, and M. Tosi. 1995. COOH–terminal substitutions in the serpin C1 inhibitor that cause loop overinsertion and subsequent multimerization. J Biol Chem. 270:2579–2587.
Theriault, A., K. Whaley, A. R. McPhaden, E. Boyd, and J. M. Connor. 1989. Regional assignment of the human C1–inhibitor gene to 11q11–q13.1. Human Genetics. 84:477–479.
Sim, R. B., A. Reboul, G. J. Arlaud, C. L. Villiers, and M. G. Colomb. 1979. Interaction of 125–labelled complement components C1r and C1 s with protease inhibitors in plasma. FEBS Lett. 97:111–115.
Ziccardi, R. J. 1981. Activation of the early components of the classical complement pathway under physiological conditions. J Immunol. 126:1768–1773.
Lennick, M., S. A. Brew, and K. C. Ingham. 1986. Kinetics of interaction of C1 inhibitor with complement C1s. Biochemistry. 25:3890–8.
Sim, R., G. Arlaud, and M. Colomb. 1980. Kinetics of reaction of human C1–inhibitor with the human complement system proteases C1r and C1s. Biochim Biophys Acta. 612:433–449.
Ziccardi, R. J., and N. R. Cooper. 1977. The subunit composition and sedimentation properties of human C1. Jlmmunol. 118:2047–2052.
Laurell, A. B., U. Martensson, and A. G. Sjoholm. 1976. C1 subcomponent complexes in normal and pathological sera studied by crossed immunoelectrophoresis. Acta Pathol Microbiol Scand. 84:455–464.
Ziccardi, R. J., and N. R. Cooper. 1979. Active disassembly of the first complement component C1 by C1–inhibitor. Jlmmunol. 123:788–792.
Tenner, A. J., and M. M. Frank. 1986. Activator–bound Cl is less susceptible to inactivation by C1 inhibition than is fluid–phase C1. Jlmmunol. 137:625–6630.
Doekes, G., L. A. van Es, and M. R. Daha. 1983. C1 inactivator: its efficiency as a regulator of classical complement pathway activation by soluble IgG aggregates. Immunology. 49:215–222.
Minta, J. O. 1981. The role of sialic acid in the functional activity and the hepatic clearance of C1–INH. J Immunol. 126:245–249.
Prandini, M. H. 1986. Biosynthesis of complement C1 inhibitor by HepG2 cells. Reactivity of different glycosylated forms of the inhibitor with C1 s. Biochem J. 237:93–98.
Reboul, A., M. H. Prandini, and M. G. Colomb. 1987. Proteolysis and deglycosylation of human C1 inhibitor. Biochem J. 244:117–121.
Patston, P. A., M. Qi, J. A. Schifferli, and M. Schapira. 1995. The effect of cleavage by a Crotalus atrox alpha–proteinase fraction on the properties of C1–inhibitor. Toxicon. 33:53–61.
Coutinho, M., K. S. Aulak, and A. E. Davis III. 1994. Functional analysis of the serpin domain of C1 inhibitor. J Immunol 153:3648,–3654.
Gigli, I., S. Ruddy, and K. F. Austen. 1968. The stoichiometric measurement of the serum inhibitor of the first component of complement by the inhibition of immune hemolysis.J Immunol 100:1154–1164.
Schapira, M., C. F. Scott, and R. W. Colman. 1982. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J Clin Invest. 69:462–468.
van der Graaf, F., J. A. Koedam, and B. N. Bouma. 1983. Inactivation of kallikrein in human plasma. J Clin Invest 71:149–158
Harpel, P. C., M. F. Lewin, and A. P. Kaplan. 1985. Distribution of plasma kallikrein between C1 inactiva–tor and a2–macroglobulin in plasma utilizing a new assay for a2–macroglobulin–kallikrein complexes. J Biol Chem. 260:4257–4263.
de Agostini, A., H. R. Lijnen, R. A. Pixley, R. W. Colman, and M. Schapira. 1984. Inactivation of factor XII active fragment in normal plasma. Predominant role of C1–inhibitor. J Clin Invest. 73:1542–1549.
Pixley, R. A., M. Schapira, and R. W. Colman. 1985. The regulation of human factor XIIa by plasma proteinase inhibitors. J Biol Chem. 260:1723 –1729.
Nuijens, J. H., A. J. M. Eerenberg–Belmer, C. C. M. Huijbregts, W. O. Schreuder, R. J. F. Felt–Bersma, J. J. Abbink, L. G. Thijs, and C. E. Hack. 1989. Proteolytic inactivation of plasma C1 inhibitor in sepsis. J Clin Invest:443–450.
Nuijens, J. H., C. C. M. Huijbregts, A. J. M. Eerenberg–Belmer, J. J. Abbink, R. J. M. Strack van Schijndel, R. J. M. Felt–Bersma, L. G. Thijs, and C. E. Hack. 1988. Quantification of plasma factor Xlia–C1–inhibitor and kallikrein–C1–inhibitor complexes in sepsis. Blood. 72:1841–1848.
Guerrero, R., F. Velasco, M. Rodriguez, A. Lopez, R. Rojas, M. A. Alvarez, R. Villalba, V. Rubio, A. Torres, and D. d. Castillo. 1993. Endotoxin–induced pulmonary dysfunction is prevented by C1–esterase inhibitor. J Clin Invest. 91:2754–2760.
Shoemaker, L. R., S. J. Schurman, V. H. Donaldson, A. E. Davis III. 1994. Hereditary angioneurotic edema: Characterization of plasma kinin and vascular permeability–enhancing activities. Clin Exp Immunol. 95:22–28.
Zahedi, R., J. J. Bissler, A. E. Davis III, C. Andreadis, and J. J. Wisnieske. 1995. Unique C1 inhibitor dysfunction in a kindred without angioedema. II. Identification of an Ala443–Val substitution and functional analysis of the recombinant mutant protein. J Clin Invest. 95:1299–1305.
Skriver, K., W. R. Wikkoff, P. A. Patston, F. Tausk, M. Schapira, A. P. Kaplan, and S. C. Bock. 1991. Substrate properties of C1 inhibitor Ma (alanine 434 glutamic acid). Genetic and structural evidence suggesting that the P12–region contains critical determinants of serine protease inhibitor/substrate status. J Biol Chem. 266:9216–9221.
Davis III, A. E., K. S. Aulak, R. B. Parad, H. P. Stecklein, E. Eldering, C. E. Hack, J. Kramer, R. C. Strunk, J. Bissler, and F. S. Rosen. 1992. C1 inhibitor hinge region mutations produce dysfunction by different mechanisms. Nature Genetics. 1:354–358.
Stein, P. E., A. G. Leslie, J. T. Finch, W. G. Turnell, P. J. McLaughlin, and R. W. Carrell. 1990. Crystal structure of ovalbumin as a model for the reactive centre of serpins. Nature. 347:99–102.
Loebermann, H., R. Tokuoka, J. Deisenhofer, and R. Huber. 1984. Human alpha 1–proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J Mol Biol 177:531–557.
Carrell, R. W., D. L. Evans, and P. E. Stein. 1991. Mobile reactive centre of serpins and the control of thrombosis. Nature. 353:576–8.
Schulze, A. J., U. Baumann, S. Knof, E. Jaeger, R. Huber, and C. B. Laurell. 1990. Structural transition of alpha 1–antitrypsin by a peptide sequentially similar to beta–strand s4A. Eur J Biochem. 194:51–6.
Levy, N. J., N. Ramesh, M. Cicardi, R. A. Harrison, and A. E. Davis III. 1990. Type II hereditary angioneurotic edema that may result from a single nucleotide change in the codon for alanine–436 in the C1 inhibitor gene. Proc Natl Acad Sci USA. 87:265–8.
Aulak, K. S., E. Eldering, C. E. Hack, Y. P. T. Lubbers, R. A. Harrison, A. Mast, M. Cicardi, and A. E. Davis III. 1993. A hinge region mutation in C1–inhibitor (Ala436Thr) results in nonsubstrate–like behavior and in polymerization of the molecule. J Biol Chem. 268:18088–94.
Carrell, R. W., D. L. Evans, and P. E. Stein. 1994. Biological implications of a 3 Å structure of dimeric antithrombin. Structure. 2:257–270.
Schreuder, H. A., B. de Boer, R. Dijkema, J. Mulders, H. J. M. Theunissen, P. D. J. Grootenhuis, and W. G. J. Hol. 1994. The intact and cleaved human antithrombin III complex as a model for serpin–proteinase interactions. Structural Biology. 1:48–54.
Stein, P. E., and R. W. Carrell. 1995. What do dysfunctional serpins tell us about molecular mobility and disease? Structural Biology. 2:96–113.
Parad, R. B., J. Kramer, R. C. Strunk, F. S. Rosen, and A. E. Davis III. 1990. Dysfunctional C1 inhibitor Ta: deletion of Lys–251 results in acquisition of an N–glycosylation site. Proc Natl Acad Sci USA. 87:6786–6790.
Zahedi, R., K. S. Aulak, E. Eldering, and A. E. Davis III. 1996. Characterization of C1 inhibitor–Ta: A dysfunctional C1 INH with deletion of lysine–251. J Biol Chem, submitted.
Stein, P. E., and C. Chothia. 1991. Serpin tertiary structure transformation. JMolecular Biology. 221:99–102.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer Science+Business Media New York
About this chapter
Cite this chapter
Davis, A.E. (1997). C1 Inhibitor. In: Church, F.C., Cunningham, D.D., Ginsburg, D., Hoffman, M., Stone, S.R., Tollefsen, D.M. (eds) Chemistry and Biology of Serpins. Advances in Experimental Medicine and Biology, vol 425. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5391-5_18
Download citation
DOI: https://doi.org/10.1007/978-1-4615-5391-5_18
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7461-9
Online ISBN: 978-1-4615-5391-5
eBook Packages: Springer Book Archive